Trajan Wealth LLC Grows Stock Holdings in Elevance Health, Inc. $ELV

Trajan Wealth LLC raised its stake in Elevance Health, Inc. (NYSE:ELV) by 6.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 92,237 shares of the company’s stock after buying an additional 5,966 shares during the period. Elevance Health makes up about 1.3% of Trajan Wealth LLC’s investment portfolio, making the stock its 20th biggest position. Trajan Wealth LLC’s holdings in Elevance Health were worth $32,334,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Murphy Middleton Hinkle & Parker Inc. purchased a new stake in shares of Elevance Health in the 4th quarter worth approximately $5,941,000. Evergreen Wealth Management LLC lifted its position in shares of Elevance Health by 33.5% in the 3rd quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock worth $5,584,000 after purchasing an additional 4,336 shares during the period. Blume Capital Management Inc. lifted its position in shares of Elevance Health by 236.7% in the 3rd quarter. Blume Capital Management Inc. now owns 6,145 shares of the company’s stock worth $1,986,000 after purchasing an additional 4,320 shares during the period. Victory Capital Management Inc. lifted its position in shares of Elevance Health by 31.1% in the 3rd quarter. Victory Capital Management Inc. now owns 461,693 shares of the company’s stock worth $149,182,000 after purchasing an additional 109,462 shares during the period. Finally, Caprock Group LLC purchased a new stake in shares of Elevance Health in the 3rd quarter worth approximately $1,638,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health Trading Down 1.5%

Shares of Elevance Health stock opened at $396.18 on Thursday. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $411.31. The firm has a market capitalization of $86.04 billion, a price-to-earnings ratio of 16.85, a PEG ratio of 2.29 and a beta of 0.66. The firm’s 50 day simple moving average is $329.59 and its two-hundred day simple moving average is $335.33.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. During the same quarter in the prior year, the business posted $11.97 EPS. Elevance Health’s revenue for the quarter was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Analysts predict that Elevance Health, Inc. will post 26.8 EPS for the current year.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. Elevance Health’s dividend payout ratio is presently 29.26%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ELV shares. Jefferies Financial Group lowered their price target on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Weiss Ratings upgraded shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday. Deutsche Bank Aktiengesellschaft upgraded shares of Elevance Health from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $363.00 to $498.00 in a research note on Wednesday. Citigroup upgraded shares of Elevance Health to a “buy” rating in a research note on Wednesday, April 29th. Finally, Robert W. Baird boosted their price objective on shares of Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. Fourteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, Elevance Health has a consensus rating of “Moderate Buy” and a consensus target price of $396.16.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.